The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Actuate Therapeutics Inc shares valued at $2,128,000 were purchased by Kairos Venture Partners II, L. on Dec 11 ’25. At $7.60 per share, Kairos Venture Partners II, L. acquired 280,000 shares.
Also, Bios Equity COF, LP purchased 71,428 shares, netting a total of over 499,996 in proceeds. Following the buying of shares at $7.00 each, the insider now holds 196,428 shares.
Before that, Kreis Leslie W. had added 71,428 shares to its account. In a trade valued at $499,996, the Director bought Actuate Therapeutics Inc shares for $7.00 each. Upon closing the transaction, the insider’s holdings increased to 71,428 shares, worth approximately $1.29 million.
As published in their initiating research note from B. Riley Securities on August 26, 2025, Actuate Therapeutics Inc [ACTU] has been a Buy and the price target has been revised to $20. Analysts at Craig Hallum started covering the stock with ‘”a Buy”‘ outlook in a report released in late April. As of March 17, 2025, H.C. Wainwright has initiated its “Buy” rating for ACTU.
Analyzing ACTU Stock Performance
On last trading session, Actuate Therapeutics Inc [NASDAQ: ACTU] plunged -0.76% to $6.56. The stock’s lowest price that day was $6.39, but it reached a high of $6.72 in the same session. During the last five days, there has been a drop of approximately -4.37%. Over the course of the year, Actuate Therapeutics Inc shares have dropped approximately -3.10%. Shares of the company reached a 52-week high of $11.99 on 05/30/25 and a 52-week low of $5.47 on 07/21/25.
Support And Resistance Levels for Actuate Therapeutics Inc (ACTU)
According to the 24-hour chart, there is a support level at 6.37, which, if violated, would cause prices to drop to 6.17. In the upper region, resistance lies at 6.78. The next price resistance is at 6.99. RSI (Relative Strength Index) is 42.14 on the 14-day chart, showing neutral technical sentiment.
Is Actuate Therapeutics Inc subject to short interest?
Stocks of Actuate Therapeutics Inc saw a sharp steep in short interest on 2025-11-28 dropping by 7736.0 shares to 0.48 million. Data from Yahoo Finance shows that the short interest on 2025-10-31 was 0.49 million shares. A decline of -1.6% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 9.71 of the overall float, the days-to-cover ratio (short ratio) decline to 9.71.
Which companies own the most shares of Actuate Therapeutics Inc (ACTU)?
In terms of Actuate Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 21 in the next 12 months, up nearly 217.7% from the previous closing price of $6.61. Analysts anticipate Actuate Therapeutics Inc stock to reach 21 by 2025, with the lowest price target being 21.
